Q-omics provides the consensus-scored AGAP5 profile across patient tissues and cancer cell-line models. AGAP5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AGAP5 is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, AGAP5 RNA expression shows 20,080 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, STAD, and UVM as cancer lineages where AGAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP5 survival associations across molecular data types. AGAP5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP5 RNA expression–survival associations across cancer types. High AGAP5 expression shows unfavorable associations in KIRC, CESC, OV and UVM, but favorable associations in HNSC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for AGAP5 RNA expression.
This table summarizes AGAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP5 shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, KIRC, COAD and LIHC. The STAD box plot shows higher AGAP5 RNA expression in tumor versus normal tissue (log2 FC = +0.234, t-test p = .003).
This table shows molecular features associated with AGAP5 in patient tissues and cancer cell lines. In patient samples, AGAP5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
